Ashwagandha Cuts Stress Scores — About as Much as a Consistent Breathing Practice

Educational journalism, not medical advice. Every claim here is checked against its cited sources by editor Tim Bunce — a health writer, not a physician. It isn’t specific to your situation: for health decisions, talk to your own clinician. How we work →

What the published trials show

• Stress and anxiety: 8-week trials with 300-600 mg daily of KSM-66 or Sensoril extracts reduced PSS-10 (Perceived Stress Scale) scores more than placebo, though 2025 meta-analyses are split on the size of the perceived-stress effect; the cortisol-lowering signal is more consistent Chandrasekhar 2012.
• Cortisol: Salivary cortisol drops 15-30% in chronically stressed adults over 8 weeks. Effect is largest in adults with elevated baseline cortisol; smaller in adults already in normal range.
• Sleep quality: Improvements in sleep-onset latency and subjective sleep scores at 8-12 weeks. Effect sizes comparable to melatonin in head-to-head trials.
• Resistance training adaptation: Small additive effects on strength and lean-mass gains in trained men over 8-12 weeks. Effect size modest Wankhede 2015.
• Testosterone: Some trials show small increases in adults with stress-related low testosterone, returning toward (not exceeding) normal range. The dramatic claims around testosterone are overstated.
• Cognitive performance: Modest improvements in memory and executive function in older adults at 8-12 weeks.

“Ashwagandha root extract at 300-600 mg daily produces clinically meaningful reductions in perceived stress and cortisol in chronically stressed adults over 8-12 weeks. The effect sizes are modest and replicable, consistent with the adaptogen rather than dramatic-intervention framework.”

— Chandrasekhar et al., Indian J Psychol Med, 2012 view source

Practical dosing

• 300-600 mg daily of a standardised root extract (KSM-66 and Sensoril are the most-studied brands; both contain ~5% withanolides).
• Take with meals to reduce mild GI side effects.
• 8-12 weeks for full effect. Don’t evaluate at 2 weeks — adaptogens build gradually.
• Consider cycling: 8-12 weeks on, 2-4 weeks off. The trial evidence doesn’t require cycling but some adults find it useful for ongoing response.

Cautions and contraindications

• Autoimmune disease. Ashwagandha may stimulate certain immune pathways. Adults with autoimmune thyroid disease (Hashimoto’s), rheumatoid arthritis, lupus, multiple sclerosis should not start without medical guidance.
• Pregnancy and lactation. Not recommended — insufficient safety data.
• Thyroid medication. Ashwagandha can raise thyroid hormone levels. Adults on levothyroxine may need dose adjustment; monitor TSH.
• Sedative medications. Benzodiazepines, anticonvulsants, sleep medications — ashwagandha can amplify sedative effects.
• Surgery. Discontinue 2 weeks before scheduled procedures due to theoretical anaesthesia interactions.
• Standard prescription medications. Discuss with a pharmacist before starting, especially if you take multiple medications.

Practical takeaways

• Ashwagandha has real published evidence for stress, anxiety, sleep quality, and modest resistance-training adaptation effects.
• The effect sizes are modest, not dramatic. Consistent daily use at standardised doses produces measurable but small improvements over 8-12 weeks.
• Dose: 300-600 mg of standardised root extract (KSM-66 or Sensoril) daily for 8-12 weeks.
• Contraindications matter: autoimmune disease, pregnancy, thyroid medication, sedatives. Talk to a doctor or pharmacist.
• Marketing claims around testosterone, immune system, and dramatic performance gains overstate the evidence.

How it actually works

The word "adaptogen" gets used so loosely in supplement marketing that it has almost stopped meaning anything. But ashwagandha (Withania somnifera) does have a plausible, increasingly mapped mechanism — and understanding it explains both why the effects are modest and why they take weeks rather than minutes to appear.

The central target is the hypothalamic–pituitary–adrenal (HPA) axis — the hormonal cascade that converts a stressor into a cortisol release. Ashwagandha's signature compounds, a family of steroidal lactones called withanolides (withaferin A is the best studied), appear to dampen an over-active HPA axis rather than blunt it indiscriminately, which is why the cortisol drop in trials is largest in people who start with elevated levels and smaller in those already in the normal range Della Porta 2023. A second strand of the mechanism is GABAergic: preclinical work indicates withanolides enhance signalling at the brain's main inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), which lowers neuronal excitability and is the same broad pathway that benzodiazepines and alcohol act on — though ashwagandha's effect is far weaker and not sedating in the same way Della Porta 2023.

It is worth being honest about the limits of this picture. Much of the GABA and anti-inflammatory (NF-κB, Nrf2) signalling work comes from cell and animal models, not humans, and the precise human pharmacology of standardised root extracts is still being worked out. What the mechanism reliably predicts, though, is the clinical shape we actually see: a gradual recalibration of a stress-response system, not an acute drug effect. That is exactly why the trials measure benefit at eight to twelve weeks and find little at two.

How strong is the cortisol and sleep evidence, really?

The single trials cited above are easy to over-read in isolation. The more useful question is what happens when you pool them. For cortisol, a 2023 systematic review in Nutrients screened nearly 4,800 records and included nine clinical trials in stressed adults, with treatment lasting 30 to 112 days. Seven trials measuring blood cortisol reported reductions of roughly 11% to 33% versus placebo, with a hint of a dose–response relationship; two trials using salivary cortisol gave contradictory results, partly because the time of day a sample is taken swamps the signal if it is not tightly controlled Della Porta 2023. The reviewers' verdict was deliberately measured: short-term supplementation "appears to have a stress-reducing effect by lowering cortisol levels," but the studies were heterogeneous in extract, dose and design, and — importantly — none checked whether suppressing cortisol had any downstream effect on adrenal function Della Porta 2023.

The sleep evidence is similarly real-but-small. A 2021 systematic review and meta-analysis in PLOS ONE pooled five randomised controlled trials (400 participants) and found a statistically significant but modest improvement in overall sleep, with a standardised mean difference of −0.59 (95% CI −0.75 to −0.42) Cheah 2021. As with cortisol, the benefit concentrated where you would expect it: the effect was larger in adults actually diagnosed with insomnia (SMD −0.84), at doses of at least 600 mg per day, and over courses of eight weeks or longer Cheah 2021. A standardised mean difference around −0.6 is, in plain terms, a meaningful nudge — comparable to other lifestyle sleep interventions — not the kind of effect you would expect from a prescription hypnotic. No serious adverse events were reported across the pooled sleep trials, though these were short studies in screened, generally healthy volunteers, which is not the same as a long-term safety guarantee for the wider population that actually buys the supplement.

The liver-safety signal worth knowing about

One caution is conspicuously missing from most ashwagandha write-ups, including this one until now: a small but documented risk of liver injury. In 2020, a case series in Liver International drawn from Iceland and the U.S. Drug-Induced Liver Injury Network (DILIN) described five adults (mean age 43) who developed jaundice, nausea, lethargy and itching two to twelve weeks after starting ashwagandha-containing supplements; the pattern was cholestatic or mixed, and liver tests returned to normal within one to five months in four of the five once the supplement was stopped Björnsson 2020. Since then, additional single-patient reports have appeared, including a young adult with a marked hepatocellular injury and severe jaundice that resolved over roughly three and a half months after discontinuation and supportive care Lubarska 2023.

Three things keep this in proportion. First, it is rare relative to how widely the supplement is used, and the published cases overwhelmingly resolved after stopping — this is not a routine outcome. Second, herbal and dietary supplements as a category now account for a substantial and rising share of drug-induced liver injury cases captured by DILIN, so ashwagandha is part of a broader pattern, not a unique villain Björnsson 2020. Third, product quality is a wildcard: supplements are not pre-approved for purity the way medicines are, and contamination or mislabelling can contribute. The practical message is simple and low-cost. If you start ashwagandha and develop yellowing of the skin or eyes, dark urine, persistent nausea, right-upper-abdominal discomfort, unusual fatigue or itching, stop it and see a clinician promptly. Anyone with existing liver disease, or who drinks heavily or takes other medications metabolised by the liver, should clear ashwagandha with a clinician or pharmacist first — and choosing a product that has been third-party tested (for example NSF or USP verified) is a sensible hedge given the lack of mandatory pre-market quality control.

The medications and conditions that change the calculus

Most healthy adults tolerate ashwagandha, but it is not inert, and its interaction profile matters more for people on prescription drugs than the marketing ever admits. A useful rule of thumb: where ashwagandha pushes the body in the same direction as a medication, the two can stack. The most clearly flagged example is thyroid hormone. The herb can nudge thyroid levels up, and there are documented cases of it tipping otherwise-healthy people into thyrotoxicosis, including a published 2024 case of painless thyroiditis that resolved only after the supplement was stopped Hayashi 2024. Anyone taking levothyroxine, or living with a thyroid or autoimmune condition, should treat ashwagandha as a drug that can interfere with their treatment, not a neutral add-on NCCIH 2023.

Several other interactions are biologically plausible but rest mostly on theory and small reports rather than robust trials. Because ashwagandha has sedative, GABA-acting effects, combining it with benzodiazepines, sleep aids, anti-seizure drugs, or alcohol could deepen drowsiness; specialists advise people on those drugs to likely avoid it, while noting the clinical relevance is not yet pinned down MSKCC 2024. It may also modestly lower blood sugar and blood pressure, so people on antidiabetic or antihypertensive medication could see additive drops and should monitor more closely NCCIH 2023. As an immune stimulant, it is a poor fit for transplant recipients or anyone on immunosuppressants like ciclosporin, where the goal is a quieter immune system Merck Manual 2024. Finally, ashwagandha should be avoided in pregnancy — it has a traditional reputation as an abortifacient — and skipped while breastfeeding, where safety data simply do not exist Merck Manual 2024. None of this makes the herb dangerous for the average user, but if you take any prescription medication, talk to your clinician or pharmacist before combining it with ashwagandha.

References